NEKTAR THERAPEUTICS Cash And Cash Equivalents At Carrying Value

• NEKTAR THERAPEUTICS showed a decrease of -65.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2010: $20.57 million | Q2 2010: $23.24 million | Q3 2010: $12.91 million | Q1 2011: $22.49 million | Q2 2011: $11.63 million | Q3 2011: $43.01 million | Q1 2012: $148.49 million | Q2 2012: $136.15 million | Q3 2012: $10.34 million | Q1 2013: $28.53 million | Q2 2013: $41.43 million | Q3 2013: $65.41 million | Q1 2014: $32.44 million | Q2 2014: $30.70 million | Q3 2014: $32.01 million | Q1 2015: $129.45 million | Q2 2015: $20.88 million | Q3 2015: $18.82 million | Q1 2016: $72.55 million | Q2 2016: $55.68 million | Q3 2016: $63.30 million | Q4 2016: $59.64 million | Q1 2017: $23.48 million | Q2 2017: $16.15 million | Q3 2017: $37.97 million | Q1 2018: $34.81 million | Q2 2018: $911.13 million | Q3 2018: $222.26 million | Q1 2019: $106.75 million | Q2 2019: $85.42 million | Q3 2019: $81.22 million | Q1 2020: $227.04 million | Q2 2020: $58.21 million | Q3 2020: $55.84 million | Q1 2021: $150.16 million | Q2 2021: $152.35 million | Q3 2021: $54.02 million | Q1 2022: $67.99 million | Q2 2022: $77.55 million | Q3 2022: $105.76 million | Q1 2023: $76.96 million | Q2 2023: $50.73 million | Q3 2023: $64.92 million | Q1 2024: $48.64 million | Q2 2024: $27.94 million | Q3 2024: $30.11 million | Q1 2025: $38.89 million | Q2 2025: $42.99 million | Q3 2025: $41.03 million.
• Over the full 18 years of available data (2008 to 2025), NEKTAR THERAPEUTICS's Cash And Cash Equivalents At Carrying Value has declined by 90.3%.
• Historical annual values: Fiscal year 2025: $15.12 million | Fiscal year 2024: $44.25 million | Fiscal year 2023: $35.28 million | Fiscal year 2022: $88.23 million | Fiscal year 2021: $25.22 million | Fiscal year 2020: $198.96 million | Fiscal year 2019: $96.36 million | Fiscal year 2018: $194.91 million | Fiscal year 2017: $4.76 million | Fiscal year 2016: $59.64 million | Fiscal year 2015: $55.57 million | Fiscal year 2014: $12.37 million | Fiscal year 2013: $39.07 million | Fiscal year 2012: $25.44 million | Fiscal year 2011: $15.31 million | Fiscal year 2010: $17.76 million | Fiscal year 2009: $49.60 million | Fiscal year 2008: $155.58 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026